Skip to main content
OpenTrials
Completed

NCT Number: NCT01306370

Fibrin Glue or Tranexamic Acid for Total Knee Arthroplasty

Objectives:

a) Principal: To assess if the fibrin glue or the tranexamic acid reduce less than 20% the blood losses with respect to the habitual haemostasia in patients with arthroplasty total of knee.

Secondaries: To assess the treatment safety. To perform a cost- analyses.

Methods: Randomized, unicentric, and parallel clinical trial with four comparative groups: Tissucol® (fibrin glue), fibrin glue manufactured by the Cryoseal® system (Banc de Sang i Teixits de Catalunya), tranexamic acid and habitual haemostasia.

Nº of participant centres: 1. Random allocation will be centralised.

Main outcome: Blood losses (ml) in the post-operatory period collected by the habitual drain system.

Secondary outcomes: Proportion of patients with blood transfusion, complications of surgery wound, pre and post-operative haemoglobin, units of blood transfused, post-operative mortality, days of hospital stay, safety of interventions assessed.

Size sample calculation: The number needed of patients is 172 (43 per group) to demonstrate a 20% difference in the post-operative blood losses between the treatments assessed and the habitual haemostasia, with a statistical power of 80% and a 0.05 bilateral alpha, and a 20% of withdrawals.

Statistical analysis: The investigators will perform a comparison of outcomes through the "t" test, the Mann-Whitney test of chi square, depending of the evaluated outcomes, quantitative or ordinals or qualitative, respectively. The software used will be Statistical Package for the Social Sciences (SPSS) version 17.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08025, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Total knee arthroplasty
  • The patient consent to participate

Exclusion criteria

  • Intolerance drugs to the study or to bovine protein (aprotinin)
  • Antecedent of thromboembolic disease
  • Patient with cardiac alterations of the rhythm
  • Patients with valvular cardiac prosthesis
  • Patients with pro-thrombotic alterations of coagulation
  • Treatment with anticonceptive drugs

Treatment and study plan

Tranexamic Acid

Drug

Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.

Each dosage: 2 ampoules of 500mg/5 mL/ampoule

Other names: Amchafibrin

Fibrin glue

Drug

Topical administration, before to close the surgical wound. Dosage: 2 mL.

Other names: Tissucol

Fibrin glue

Biological

Topical administration, before to close the surgical wound.

Habitual haemostasis

Other

The surgical habitual haemostasis.

Primary outcomes

  1. Postoperative blood loss (mL)

    Time frame: During the first 48h after the surgical intervention

    Blood loss (mL) by the surgical wound collected by drain systems.

Secondary outcomes

  1. Percentage of patients that need a postoperative blood transfusion

    Time frame: During the first postoperative week

  2. Percentage of patients with surgical wound infection

    Time frame: During the first postoperative month

  3. Percentage of patients with surgical wound dehiscence

    Time frame: During the first postoperative month

  4. Percentage of patients with re-intervention by wound complications

    Time frame: During the first postoperative month

  5. Incidence of deep venous thrombosis

    Time frame: During the first postoperative week

  6. Pain of surgical wound

    Time frame: During the first postoperative week

  7. Units of blood transfusion

    Time frame: During the first postoperative week

  8. hospital length stay

    Time frame: Days

  9. Mortality

    Time frame: During the first postoperative month

Sponsors and collaborators

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Other

Collaborators

  • Banc de Sang i Teixits

Registry information

Official study title

Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.

Acronym: ATRHEMOS

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Mar 1, 2011
Registry last updated
Aug 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.